Citron Research says Valeant Pharma (VRX) has better chance than HLF of 'going to $0'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday
November 1, 2015 7:32 PM ESTCitron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.
During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Citron's Left Will be on CNBC Monday to Talk About Valeant (VRX)
October 30, 2015 12:27 PM EDTCitron's Andrew Left will be back on CNBC's Halftime Report on Monday, November 2nd, to talk about his upcoming report on Valeant Pharma (NYSE: VRX).
... More